The Pharmaceutical Society of Australia (PSA) has announced the Quality Use of Medicines Alliance (QUM Alliance) is expanding into new clinical topic areas.
These include:
- Menopause,
- Secondary stroke prevention,
- Antidepressants in teens and young adults,
- Osteoporosis, and
- Complex comorbidity.
This expansion builds on the QUM Alliance’s existing work in conditions such as atopic dermatitis, gout, antidepressant use in older people, and oral anticoagulant use in patients with atrial fibrillation, and is supported by the Australian Government’s Quality Use of Diagnostics, Therapeutics and Pathology (QUDTP) Program.
“PSA is proud to be a part of the QUM Alliance, championing the collaborative learning of all health professionals on some of Australia’s most prevalent health issues,” says PSA National President Associate Professor Fei Sim FPS.
“PSA is leading the way for QUM education, representing the pharmacy profession and working closely with other Alliance members to upskill not only pharmacists but also other health professionals and consumers.
“We look forward to continuing this important work over the next three years, and encourage pharmacists across all areas of practice to engage with the QUM Alliance resources.”
The QUM Alliance — an initiative comprising health and consumer organisations — is delivering nationally available, free educational resources to health professionals and consumers.
Current PSA education offerings produced as part of the QUM Alliance are available: QUM Alliance.
